5-HT2A receptor blockade in patients with schizophrenia treated with risperidone or clozapine: A SPET study using the novel 5-HT2A ligand 1231-5-1-R-91150
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Background: 5-HT 2A receptor antagonism may be crucial to the action of atypical antipsychotics. Previous work has related 5-HT 2A receptor blockade to clinical efficacy and protection from extrapyramidal side-effects. Method: We developed a SPET imaging protocol for assessing 5-HT 2A receptor binding using the selective ligand 123 1-5-1-R91150. Six healthy volunteers, five clozapine- and five risperidone-treated subjects with DSM–IV schizophrenia were studied. Multi-slice SPET was performed on each subject. Results: Cortex: cerebellum ratios were significantly lower in both clozapine-and risperidone-treated subjects compared with the healthy volunteers in all cortical regions. There was no difference in occupancy between the two drug-treated groups. No correlation was found between the percentage change in the Global Assessment Scale (GAS) and 5-HT 2A receptor binding indices in the drug-treated groups. Conclusions: Clozapine and risperidone potently block 5-HT 2A receptors in vivo. The lack of relationship between receptor binding indices and change in GAS suggests that 5-HT 2A receptor blockade may be unrelated to clinical improvement. Future studies will substantiate this finding by studying 5-HT 2A receptor binding in large groups of patients treated with both typical and novel atypical antipsychotics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Serotonin receptors in the human brain—IV. Autoradiographic mapping of serotonin-2 receptors
Pazos, A., Probst, A., & Palacios, J. M. (1987) · Neuroscience · doi:10.1016/0306-4522(87)90327-7 · Cited by 355
Cited by
Serotonin receptors : their key role in drugs to treat schizophrenia
Meltzer, H. Y., Li, Z., Kaneda, Y., & Ichikawa, J. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2003.09.010 · Cited by 775
Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research
Arranz, M. J., & de Leon, J. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4002009 · Cited by 351
Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment
Konradi, C., & Heckers, S. (2003) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(02)00328-5 · Cited by 336
“…Nyberg et al., 1997; Pilowsky et al., 1996; Prinssen et al., 1994; Raedler et al., 1999; Richelson, 1999; Seeman, 1992; Stockmeier et al., 1993; Travis et al., 1998; Trichard et al., 1998; Zorn et al., 1994), but none of these effects predominate or can explain satisfactorily the mechanism of…”
BackgroundPharmacogenetics of antipsychotic-induced weight gain: review and clinical implications
Lett, T. A. P., Wallace, T. J. M., Chowdhury, N. I., Tiwari, A. K., Kennedy, J. L., & Müller, D. J. (2012) · Molecular Psychiatry · doi:10.1038/mp.2011.109 · Cited by 264
van Heeringen, C., Audenaert, K., Van Laere, K., Dumont, F., Slegers, G., Mertens, J., & Dierckx, R. A. (2003) · Journal of Affective Disorders · doi:10.1016/s0165-0327(01)00482-7 · Cited by 200
Self-citation
Metadata
- Authors
- Travis, M. J., Busatto, G. F., Pilowsky, L. S., Mulligan, R., Acton, P. D., Gacinovic, S., Mertens, J., Terrière, D., Costa, D. C., Ell, P. J., & Kerwin, R. W.
- Venue
- British Journal of Psychiatry
- Publisher
- Royal College of Psychiatrists
- Published
- 1998-09
- Volume
- 173
- Issue
- 3
- Pages
- 236-241
- ISSN
- 0007-1250 (ISSN-L)
- 1472-1465
- OpenAlex
- W2137925486
- Cited by
- 69
- References
- 1
- FWCI
- 3.72
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.